Hematopoietic progenitor cell transplantation in multiple myeloma

The median survival of conventionally treated patients with multiple myeloma is 3 years. Modifications of conventional chemotherapy and the administration of interferon-α have failed to show an improved survival in most randomized trials. Therapy with dose-escalated alkylating agents (i. e. melphala...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Goldschmidt, Hartmut (VerfasserIn) , Hegenbart, Ute (VerfasserIn) , Haas, Rainer (VerfasserIn) , Hunstein, Werner (VerfasserIn)
Dokumenttyp: Article (Journal)
Sprache:Englisch
Veröffentlicht: 1995
In: Onkologie
Year: 1995, Jahrgang: 18, Heft: 6, Pages: 518-523
ISSN:1423-0240
DOI:10.1159/000218652
Online-Zugang:Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1159/000218652
Volltext
Verfasserangaben:H. Goldschmidt, U. Hegenbart, R. Haas, W. Hunstein
Beschreibung
Zusammenfassung:The median survival of conventionally treated patients with multiple myeloma is 3 years. Modifications of conventional chemotherapy and the administration of interferon-α have failed to show an improved survival in most randomized trials. Therapy with dose-escalated alkylating agents (i. e. melphalan 140 mg/m2) induced higher remission rates than conventional treatment. If followed by allogeneic or autologous hematopoietic progenitor cell transplantation, the hematotoxicity of the described dose-escalated treatment could be reduced. Results of transplantation trials are summarized and discussed. The transplantation of autologous peripheral blood progenitor cells results in a faster hematopoietic reconstitution and a decreased high-dose therapy-related morbidity compared to autologous bone marrow and should therefore be preferred. Although the randomized French myeloma trial showed a significant survival advantage for patients following autologous transplantation, further randomized prospective studies are required to evaluate the role of blood progenitor cell transplantation after high-dose treatment in multiple myeloma. Prognostical factors and future treatment modalities for myeloma are discussed.
Beschreibung:Elektronische Reproduktion der Druck-Ausgabe 11. Mai 2009
Gesehen am 15.05.2025
Beschreibung:Online Resource
ISSN:1423-0240
DOI:10.1159/000218652